These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 2567579

  • 1. Effects of topical treatment with H1 and H2 antagonists on clinical symptoms and nasal vascular reactions in patients with allergic rhinitis.
    Holmberg K, Pipkorn U, Bake B, Blychert LO.
    Allergy; 1989 May; 44(4):281-7. PubMed ID: 2567579
    [Abstract] [Full Text] [Related]

  • 2. Effect of a new selective H1 receptor antagonist (levocabastine) in a nasal and conjunctival provocation test.
    Pécoud A, Zuber P, Kolly M.
    Int Arch Allergy Appl Immunol; 1987 May; 82(3-4):541-3. PubMed ID: 2883132
    [Abstract] [Full Text] [Related]

  • 3. Effects of topical budesonide and levocabastine on nasal symptoms and plasma exudation responses in seasonal allergic rhinitis.
    Svensson C, Andersson M, Greiff L, Blychert LO, Persson CG.
    Allergy; 1998 Apr; 53(4):367-74. PubMed ID: 9574878
    [Abstract] [Full Text] [Related]

  • 4. Effect of topical levocabastine on nasal response to allergen challenge and nasal hyperreactivity in perennial rhinitis.
    de Graaf-in 't Veld T, Garrelds IM, van Toorenenbergen AW, Mulder PG, Gerth van Wijk R, Boegheim JP.
    Ann Allergy Asthma Immunol; 1995 Sep; 75(3):261-6. PubMed ID: 7552929
    [Abstract] [Full Text] [Related]

  • 5. Effect of H1 and H2 antagonists on nasal symptoms and mediator release in atopic patients after nasal allergen challenge during the pollen season.
    Wang D, Clement P, Smitz J.
    Acta Otolaryngol; 1996 Jan; 116(1):91-6. PubMed ID: 8820358
    [Abstract] [Full Text] [Related]

  • 6. Onset and duration of action of levocabastine nasal spray in atopic patients under nasal challenge conditions.
    Corren J, Rachelefsky G, Spector S, Schanker H, Siegel S, Holton D, Karcher K, Travers S.
    J Allergy Clin Immunol; 1999 Apr; 103(4):574-80. PubMed ID: 10200003
    [Abstract] [Full Text] [Related]

  • 7. Intranasal levocabastine provides fast and effective protection from nasal allergen challenge.
    Bachert C, Wagenmann M, Vossen-Holzenkamp S.
    Rhinology; 1996 Sep; 34(3):140-3. PubMed ID: 8938880
    [Abstract] [Full Text] [Related]

  • 8. Effect of systemically administered H1- and H2-receptor antagonists on nasal blood flow as measured with laser Doppler flowmetry in a provoked allergic reaction.
    Juliusson S, Bende M.
    Rhinology; 1996 Mar; 34(1):24-7. PubMed ID: 8739864
    [Abstract] [Full Text] [Related]

  • 9. Inhibitory effect of levocabastine on allergen-induced increase of nasal reactivity to histamine and cell influx.
    Pazdrak K, Górski P, Ruta U.
    Allergy; 1993 Nov; 48(8):598-601. PubMed ID: 7906926
    [Abstract] [Full Text] [Related]

  • 10. The effects of an H3 receptor antagonist (PF-03654746) with fexofenadine on reducing allergic rhinitis symptoms.
    Stokes JR, Romero FA, Allan RJ, Phillips PG, Hackman F, Misfeldt J, Casale TB.
    J Allergy Clin Immunol; 2012 Feb; 129(2):409-12, 412.e1-2. PubMed ID: 22196768
    [Abstract] [Full Text] [Related]

  • 11. Significance of H1 and H2 receptors in the human nose: rationale for topical use of combined antihistamine preparations.
    Secher C, Kirkegaard J, Borum P, Maansson A, Osterhammel P, Mygind N.
    J Allergy Clin Immunol; 1982 Sep; 70(3):211-8. PubMed ID: 6179976
    [Abstract] [Full Text] [Related]

  • 12. Topical levocabastine, a selective H1 antagonist, in seasonal allergic rhinoconjunctivitis.
    Bende M, Pipkorn U.
    Allergy; 1987 Oct; 42(7):512-5. PubMed ID: 2891316
    [Abstract] [Full Text] [Related]

  • 13. Experimentally induced nasal hypersecretion does not reduce the efficacy of intranasal levocabastine.
    Borum S, Nielsen K, Bisgaard H, Mygind N.
    Rhinology; 1998 Dec; 36(4):153-5. PubMed ID: 9923056
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The effects of combined H1 and H2 histamine antagonists on alterations in nasal airflow resistance induced by topical histamine provocation.
    Havas TE, Cole P, Parker L, Oprysk D, Ayiomamitis A.
    J Allergy Clin Immunol; 1986 Nov; 78(5 Pt 1):856-60. PubMed ID: 2878016
    [Abstract] [Full Text] [Related]

  • 16. Comparison of levocabastine, a new selective H1-receptor antagonist, and disodium cromoglycate, in a nasal provocation test with allergen.
    Kolly M, Pécoud A.
    Br J Clin Pharmacol; 1986 Oct; 22(4):389-94. PubMed ID: 2876723
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of levocabastine nasal spray for seasonal allergic rhinitis.
    Hampel FC, Martin BG, Dolen J, Travers S, Karcher K, Holton D.
    Am J Rhinol; 1999 Oct; 13(1):55-62. PubMed ID: 10088031
    [Abstract] [Full Text] [Related]

  • 18. The effect of levocabastine nasal spray in nasal provocation tests.
    Palma-Carlos AG, Palma-Carlos ML, Rombaut N.
    Int J Clin Pharmacol Res; 1988 Oct; 8(1):25-30. PubMed ID: 2896636
    [Abstract] [Full Text] [Related]

  • 19. Clinical efficacy and pharmacokinetic profiles of intranasal and oral cetirizine in a repeated allergen challenge model of allergic rhinitis.
    Korsgren M, Andersson M, Borgå O, Larsson L, Aldén-Raboisson M, Malmqvist U, Greiff L.
    Ann Allergy Asthma Immunol; 2007 Apr; 98(4):316-21. PubMed ID: 17458426
    [Abstract] [Full Text] [Related]

  • 20. Low dose clemastine inhibits sneezing and rhinorrhea during the early nasal allergic reaction.
    Chung JH, deTineo ML, Naclerio RM, Sorrentino JV, Winslow CM, Baroody FM.
    Ann Allergy Asthma Immunol; 1997 Mar; 78(3):307-12. PubMed ID: 9087158
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.